Neuroprotective effects of metabotropic glutamate receptor group II and III activators against MPP(+)-induced cell death in human neuroblastoma SH-SY5Y cells: the impact of cell differentiation state.
作者： D. Jantas , A. Greda , S. Golda , M. Korostynski , B. Grygier
DOI: 10.1016/J.NEUROPHARM.2014.03.019
关键词: AMN082 、 SH-SY5Y 、 Cell growth 、 Pharmacology 、 Agonist 、 Metabotropic glutamate receptor 、 Neuroprotection 、 Neurotoxin 、 Biochemistry 、 Chemistry 、 HYDIA
摘要: Recent studies have documented that metabotropic glutamate receptors from group II and III (mGluR II/III) are a potential target in the symptomatic treatment of Parkinson's disease (PD), however, the neuroprotective effects of particular mGluR II/III subtypes in relation to PD pathology are recognized only partially. In the present study, we investigated the effect of various mGluR II/III activators in the in vitro model of PD using human neuroblastoma SH-SY5Y cell line and mitochondrial neurotoxin MPP (+). We demonstrated that all tested …
core.ac.uk
elsevier.com
researchgate.net 
sci-hub.se 参考文章(103)
Fiona Thomson, Parkinson's Disease Neuron. ,vol. 39, pp. 889- 909 ,(2003) , 10.1016/S0896-6273(03)00568-3
James A. Monn, Matthew J. Valli, Steven M. Massey, Rebecca A. Wright, Craig R. Salhoff, Bryan G. Johnson, Trevor Howe, Charles A. Alt, Gary A. Rhodes, Roger L. Robey, Kelly R. Griffey, Joseph P. Tizzano, Mary J. Kallman, David R. Helton, Darryle D. Schoepp, Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. Journal of Medicinal Chemistry. ,vol. 40, pp. 528- 537 ,(1997) , 10.1021/JM9606756
Susan Duty, Peter Jenner, Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease British Journal of Pharmacology. ,vol. 164, pp. 1357- 1391 ,(2011) , 10.1111/J.1476-5381.2011.01426.X
S. Cardoso, P. Moreira, P. Agostinho, C. Pereira, C. Oliveira, Neurodegenerative Pathways in Parkinsons Disease: Therapeutic Strategies Current Drug Targets - Cns & Neurological Disorders. ,vol. 4, pp. 405- 419 ,(2005) , 10.2174/1568007054546072
Susan Duty, Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease British Journal of Pharmacology. ,vol. 161, pp. 271- 287 ,(2010) , 10.1111/J.1476-5381.2010.00882.X
Robert M. Duvoisin, Tim Pfankuch, Julie M. Wilson, Julie Grabell, Vijay Chhajlani, Dean G. Brown, Edwin Johnson, Jacob Raber, Acute pharmacological modulation of mGluR8 reduces measures of anxiety Behavioural Brain Research. ,vol. 212, pp. 168- 173 ,(2010) , 10.1016/J.BBR.2010.04.006
Joanna A. Korecka, Ronald E. van Kesteren, Eva Blaas, Sonia O. Spitzer, Jorke H. Kamstra, August B. Smit, Dick F. Swaab, Joost Verhaagen, Koen Bossers, Phenotypic Characterization of Retinoic Acid Differentiated SH-SY5Y Cells by Transcriptional Profiling PLOS ONE. ,vol. 8, pp. 63862- ,(2013) , 10.1371/JOURNAL.PONE.0063862
Filippo Caraci, Giuseppe Battaglia, Maria Angela Sortino, Simona Spampinato, Gemma Molinaro, Agata Copani, Ferdinando Nicoletti, Valeria Bruno, Metabotropic glutamate receptors in neurodegeneration/neuroprotection: Still a hot topic? Neurochemistry International. ,vol. 61, pp. 559- 565 ,(2012) , 10.1016/J.NEUINT.2012.01.017
Luisa Iacovelli, Ferdinando Nicoletti, Antonio De Blasi, Molecular mechanisms that desensitize metabotropic glutamate receptor signaling: An overview Neuropharmacology. ,vol. 66, pp. 24- 30 ,(2013) , 10.1016/J.NEUROPHARM.2012.05.005
STEFANIA BRADLEY, DAVID G. STANDAERT, ALLAN I. LEVEY, P. JEFFREY CONN, Distribution of Group III mGluRs in Rat Basal Ganglia with Subtype‐Specific Antibodies Annals of the New York Academy of Sciences. ,vol. 868, pp. 531- 534 ,(1999) , 10.1111/J.1749-6632.1999.TB11322.X